Erratum: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) (Eur Heart J (2021) 42 (373-498) DOI: 10.1093/eurheartj/ehaa612)

Abstract

In the originally published version of thismanuscript, several errors were noted and listed in this corrigendum. Upon original publication, the legend of Figure 2. included the following citation: "Di Carlo, et al. Europace, 2019; 21:1468-1475. PMID: 31131389" instead of "Ko D, et al". Upon original publication, there were some inaccuracies recorded in Supplementary Figure 6. which have been updated. Upon original publication, the following text under the "Screening types and strategies" section should read: "or general practice vs. community screening in a meta-analysis, but repeated heart rhythm monitoring associated with significantly better effectiveness". Upon original publication, the last text bubble heading in Figure 9. should read: "Value of Imaging techniques in AF". Upon original publication, Table 11. indicated that the lower of Edoxaban dose was "30 mg o.d.". This has now been deleted.In the same table, the following Dose-reduction criteria for Edoxaban should read: "CrCl 15-50 mL/min" instead of "CrCl 30-50 mL/min". Upon original publication, the following text under sub-section 10.2.1.3 Acute rate control, should read: "and haemodynamics, but a lenient initial rate control approach". Upon original publication, the Landiolol results under the "Beta-blockersb" heading in Table 13. was inaccurately referenced with citation 505. This has been deleted. In addition, the following result was omitted from the same cell: "in patients with cardiac dysfunction: 1-10 mg/kg/min" GH". This has been added. Upon original publication, Figure 16. inaccurately recorded the following cells: "AF onset <12 hours OR 12-<48 hours" and "AF onset-48 hours or unknown". These have now been deleted. Upon original publication, the arrow leading from "Catheter ablation" to "Perform catheter ablation" in Figure 17. should be changed from solid to doted. Upon original publication, Table 20. inaccurately indicated that Sotalol (d,l racemic mixture) should not be used if CrCl <50 mL/min. This has now been deleted. Upon original publication, the "Recommendations for lifestyle interventions and management of risk factors and concomitant diseases in patients with AF" inaccurately referenced the following citations for the "Optimal management of OSA may be considered, to reduce AF incidence, AF progression, AF recurrences, and symptoms" cell: "1057-1061, 1064, 1065" instead of "1047-1051". Upon original publication, Figure 13. was inaccurately tagged with the ESC copyright. This has been deleted. The following cells of the "Recommendations for patients with AF and an ACS, PCI, or CCS" have been updated as follows: For "In AF patients with ACS undergoing an uncomplicated PCI, early cessation (1 week) of aspirin and continuation of dual therapy with an OAC and a P2Y12 inhibitor (preferably clopidogrel) for up to 12 months is recommended if the risk of stent thrombosisd is low or if concerns about bleeding riske prevail over concerns about risk of stent thrombosis,d irrespective of the type of stent used", the Level of Evidence should be "A". For "After uncomplicated PCI, early cessation (1 week) of aspirin and continuation of dual therapy withOAC for up to 6 months and clopidogrel is recommended if the risk of stent thrombosisd is low or if concerns about bleeding riske prevail over concerns about risk of stent thrombosis,d irrespective of the type of stent used.", the Level of Evidence should be "A". Upon original publication, the following recommendations for "Recommendations for surgical ablation of AF" should read in part: "with evident risk factors for catheter ablation failure, tomaintain long-term sinus rhythm". Upon original publication, the following sentence in the "Atrial fibrillation in inherited cardiomyopathies and primary arrhythmia syndromes" section should read: "Pharmacological cardioversion can be attempted using ibutilide,1339 whereas AADs class Ia (procainamide) and Ic (propafenone, flecainide) should be used with caution owing to their effect on the atrioventricular node.".